<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01986543</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 12292 RIFAVIRENZ</org_study_id>
    <nct_id>NCT01986543</nct_id>
  </id_info>
  <brief_title>Interaction Between High Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infection</brief_title>
  <acronym>RIFAVIRENZ</acronym>
  <official_title>Interaction Between High Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ANRS, Emerging Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ANRS, Emerging Infectious Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We propose a first interaction study between efavirenz (EFV) and R20mg/Kg taking into&#xD;
      consideration the absence of data about R induction at this dose. Due to an important&#xD;
      inter-patient variability of the CYP2B6 polymorphism, the EFV pharmacokinetic (Pk) will be&#xD;
      compared in same patients with and without TB treatment.&#xD;
&#xD;
      The main objective is to compare the Pk parameters of EFV in HIV-TB co-infected patients,&#xD;
      with and without TB treatment, using R at 10 and 20mg/Kg/day and EFV at 600 and 800mg/day.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Justification: In vitro and animal studies have shown that increasing the dose of rifampicin&#xD;
      (R) improves the R sterilising effect. If a similar effect can be demonstrated in the&#xD;
      clinical setting, this could allow shortening treatment duration from 6 to 4 months, with&#xD;
      good tolerance. Several phase 2 trials in HIV-negative patients are ongoing. We propose a&#xD;
      first interaction study between efavirenz (EFV) and R20mg/Kg taking into consideration the&#xD;
      absence of data about R induction at this dose. Due to an important inter-patient variability&#xD;
      of the CYP2B6 polymorphism, the EFV pharmacokinetic (Pk) will be compared in same patients&#xD;
      with and without TB treatment.&#xD;
&#xD;
      Principal objective: To compare the Pk parameters of EFV in HIV-TB co-infected patients, with&#xD;
      and without TB treatment, using R at 10 and 20mg/Kg/day and EFV at 600 and 800mg/day.&#xD;
&#xD;
      Secondary objectives: To describe the Pk parameters of R and isoniazid (H); the TB treatment&#xD;
      réponse (Mycobacterium tuberculosis culture conversion after 8 weeks(w) and cure after 24w) ;&#xD;
      the virological response; the occurrence of severe adverse events, especially hepatic and&#xD;
      neurological events; the treatment adherence; the genes involved in the EFV metabolism of&#xD;
      EFV, R and H, and its relation with the Pk parameters.&#xD;
&#xD;
      Primary endpoint: AUC0-24, Cmax, Cmin, Tmax of EFV after 4w of TB treatment + ARV, and 4w&#xD;
      after interruption of TB treatment.&#xD;
&#xD;
      Study design : phase 2 randomized, open label 3 arms therapeutic trial:&#xD;
&#xD;
        -  Arm 1 : 8 weeks R20mg/Kg + H + pyrazinamide(Z)+ ethambutol(E) and EFV600mg/J +&#xD;
           tenofovir-lamivudine&#xD;
&#xD;
        -  Arm 2: 8 weeks R20mg/Kg + H+Z+E and EFV800mg/J + tenofovir-lamivudine&#xD;
&#xD;
        -  Standard arm : 8 weeks R10mg/Kg + H+Z+E and EFV600mg/J + tenofovir-lamivudine&#xD;
&#xD;
      The ARV treatment will be initiated 4 weeks after starting TB treatment. After 8 weeks, all&#xD;
      patients will receive 16 weeks of H+R with R at 10mg/Kg/day and EFV at 600mg/day. Treatment&#xD;
      will be observed at home by a domiciliary treatment monitor (DTM). Patients will be followed&#xD;
      during 28 weeks after starting TB treatment: weekly visit during first 8 weeks and then every&#xD;
      4 weeks.&#xD;
&#xD;
      Pk sampling for EFV, R and H will be at w2 (Pk1), w8 (Pk2) and w28 (Pk3). Liver function test&#xD;
      and full blood count will be measured after 2, 4 and 8 weeks; sputum culture for TB at&#xD;
      baseline and w8; HIV-1 RNA at baseline, w4, w12 and w24 and CD4 count at baseline and w24.&#xD;
&#xD;
      Eligibility criteria: &gt; 18 years old; previously untreated pulmonary TB; Xpert confirming Mtb&#xD;
      susceptible to R; body weight &gt;45Kg; CD4 between 50 and 250cells/mm3; Karnofsky score &gt;80%;&#xD;
      ALAT/biluribin &lt;5xULN; no grade 4 clinical/biological sign; no pregnancy + barrier&#xD;
      contraception; agree to participate and sign a consent form.&#xD;
&#xD;
      Randomisation block, 1:1:1. Sample size: 28 patients to show that the reduction of AUC of EFV&#xD;
      with R20mg/Kg vs no R is not greater to 30%, with 20% expected reduction. Same number per&#xD;
      study arm and 20% increase for patients' withdrawals or lost to follow-up resulting in a&#xD;
      total of 105 patients.&#xD;
&#xD;
      Site: Mbarara (Uganda)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efavirenz through concentration before drug intake (Cmin); maximal concentration (Cmax); time to achieve the Cmax (Tmax) and area under the curve of concentrations vs time at steady state during a 24-hour dosing interval (AUC0-24)</measure>
    <time_frame>Week 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efavirenz Cmin; Cmax; Tmax; AUC0-24</measure>
    <time_frame>Week 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of R and H (Cmin, Cmax and AUC0-24)</measure>
    <time_frame>Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of R and H (Cmin, Cmax and AUC0-24)</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mycobacterium tuberculosis culture of sputum</measure>
    <time_frame>week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma HIV-1 RNA</measure>
    <time_frame>week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3 and 4 adverse events</measure>
    <time_frame>0-28 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Tuberculosis</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 weeks R20mg/Kg + HZE and efavirenz 600mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 weeks R20mg/Kg + HZE and efavirenz 800mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 weeks R10mg/Kg + HZE and efavirenz 600mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>drug administration</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Standard arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged of 18 years or more&#xD;
&#xD;
          -  Diagnosis of new pulmonary tuberculosis confirmed by a XpertMTB/RIF test&#xD;
&#xD;
          -  Positive HIV antibody test, naïve of ART with CD4 cell count between 50 and&#xD;
             250cells/mm3&#xD;
&#xD;
          -  For women of childbearing age, to have a negative urine test for pregnancy on the day&#xD;
             of enrolment and to accept to take a barrier contraception during the period of the&#xD;
             trial&#xD;
&#xD;
          -  Participants well enough to receive ambulatory treatment&#xD;
&#xD;
          -  Weight &gt; 45Kg&#xD;
&#xD;
          -  Home address readily accessible&#xD;
&#xD;
          -  Participants providing informed consent to participate in the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Rifampicin drug resistance based on the XpertMTB/RIF result confirmed by the&#xD;
             GenotypeMTBDRplus assay&#xD;
&#xD;
          -  Concomitant opportunistic infection requiring additional infectious medication&#xD;
&#xD;
          -  Karnofsky score &lt;80%&#xD;
&#xD;
          -  ALAT or bilirubin &gt; 5.0 x ULN (hepatitis grade 3 or 4)&#xD;
&#xD;
          -  Haemoglobin &lt; 7.5g/dL (grade 3 or 4)&#xD;
&#xD;
          -  Grade 4 clinical sign or biological result according to the ANRS for grading the&#xD;
             intensity of adverse events&#xD;
&#xD;
          -  Patient not able to give his informed consent or is unlikely or unable to cooperate&#xD;
             with sampling procedures&#xD;
&#xD;
          -  Patient suffering of psychiatric illness, which may prevent follow-up according to the&#xD;
             protocol&#xD;
&#xD;
          -  Patients receiving or requiring medications that may interfere with study drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BONNET Maryline, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Epicentre MSF</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mbarara Research Base</name>
      <address>
        <city>Mbarara PO box 1956, Mbarara</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>November 12, 2013</study_first_submitted>
  <study_first_submitted_qc>November 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2013</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
    <mesh_term>Coinfection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

